| Comprehensive molecular portraits of human breast tumours Brigham & Women’s Hospital & Harvard Medical School Chin Lynda 9 11 Park ... Nature 490 (7418), 61-70, 2012 | 11162 | 2012 |
| Comprehensive molecular characterization of gastric adenocarcinoma Cancer Genome Atlas Research Network Nature 513 (7517), 202, 2014 | 5228 | 2014 |
| Comprehensive genomic characterization of head and neck squamous cell carcinomas Cancer Genome Atlas Network Nature 517 (7536), 576, 2015 | 3286 | 2015 |
| Improved overall survival in melanoma with combined dabrafenib and trametinib C Robert, B Karaszewska, J Schachter, P Rutkowski, A Mackiewicz, ... New England Journal of Medicine 372 (1), 30-39, 2015 | 2929 | 2015 |
| Genomic classification of cutaneous melanoma R Akbani, KC Akdemir, B áArman Aksoy, M Albert, A Ally, SB Amin, ... Cell 161 (7), 1681-1696, 2015 | 2717 | 2015 |
| Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma C Robert, JJ Grob, D Stroyakovskiy, B Karaszewska, A Hauschild, ... New England Journal of Medicine 381 (7), 626-636, 2019 | 1201 | 2019 |
| The soluble interleukin‐6 receptor is generated by shedding J Mülberg, H Schooltink, T Stoyan, M Günther, L Graeve, G Buse, ... European journal of immunology 23 (2), 473-480, 1993 | 664 | 1993 |
| Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial PA Ascierto, M Del Vecchio, C Robert, A Mackiewicz, V Chiarion-Sileni, ... The Lancet Oncology 18 (5), 611-622, 2017 | 514 | 2017 |
| Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. A Mackiewicz, H Schooltink, PC Heinrich, S Rose-John Journal of immunology (Baltimore, Md.: 1950) 149 (6), 2021-2027, 1992 | 481 | 1992 |
| Characterization of HPV and host genome interactions in primary head and neck cancers M Parfenov, CS Pedamallu, N Gehlenborg, SS Freeman, L Danilova, ... Proceedings of the National Academy of Sciences 111 (43), 15544-15549, 2014 | 423 | 2014 |
| Interleukin‐6 serum levels in depressed patients before and after treatment with fluoxetine A Służewska, JK Rybakowski, M Laciak, A Mackiewicz, M Sobieska, ... Annals of the New York Academy of Sciences 762 (1), 474-476, 1995 | 398 | 1995 |
| Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. A Mackiewicz, T Speroff, MK Ganapathi, I Kushner Journal of immunology (Baltimore, Md.: 1950) 146 (9), 3032-3037, 1991 | 330 | 1991 |
| Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised … AMM Eggermont, CU Blank, M Mandalà, GV Long, VG Atkinson, S Dalle, ... The Lancet Oncology 22 (5), 643-654, 2021 | 315 | 2021 |
| Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous … JJ Grob, MM Amonkar, B Karaszewska, J Schachter, R Dummer, ... The Lancet Oncology 16 (13), 1389-1398, 2015 | 285 | 2015 |
| A high proportion of founder BRCA1 mutations in Polish breast cancer families B Górski, A Jakubowska, T Huzarski, T Byrski, J Gronwald, E Grzybowska, ... International journal of cancer 110 (5), 683-686, 2004 | 256 | 2004 |
| Aspects of the tumor microenvironment involved in immune resistance and drug resistance K Khalaf, D Hana, JTT Chou, C Singh, A Mackiewicz, M Kaczmarek Frontiers in immunology 12, 656364, 2021 | 242 | 2021 |
| Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial M Maio, K Lewis, L Demidov, M Mandalà, I Bondarenko, PA Ascierto, ... The Lancet Oncology 19 (4), 510-520, 2018 | 230 | 2018 |
| Microheterogeneity of alpha-fetoprotein in patient serum as demonstrated by lectin affino-electrophoresis. J Breborowicz, A Mackiewicz, D Breborowicz Scandinavian Journal of Immunology 14 (1), 1981 | 208 | 1981 |
| Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 D Hannani, M Vetizou, D Enot, S Rusakiewicz, N Chaput, D Klatzmann, ... Cell research 25 (2), 208-224, 2015 | 196 | 2015 |
| Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials D Schadendorf, GV Long, D Stroiakovski, B Karaszewska, A Hauschild, ... European Journal of Cancer 82, 45-55, 2017 | 194 | 2017 |
